A rationally designed neuraminidase immunogen elicits humoral responses to a conserved viral site
Hecht, R.; Nait Mohamed, F. A.; Zhang, S.; Rawson, S.; Lee, S. E.; Murphy, C. L.; Thornlow Lamson, D.; Ronsard, L.; Caradonna, T. M.; Lingwood, D.; Schmidt, A. G.
Show abstract
Efforts to develop a universal influenza vaccine have primarily focused on the surface-exposed viral hemagglutinin (HA), but neuraminidase (NA) is an additional target for cross-reactive, protective responses. Here, we used hyperglycosylation as an immunogen design approach to reshape anti-NA humoral immunity toward conserved antigenic regions. Iterative design produced a hyperglycosylated NA immunogen that retained enzymatic activity and reactivity to a conformation-specific antibody recognizing the conserved catalytic site. In mice, the hyperglycosylated immunogen elicited serum antibody responses of comparable magnitude to those elicited by the wild-type NA immunogen. However, serum antibodies elicited by the hyperglycosylated immunogen had increased breadth, recognizing N2 NAs from H2N2 and H3N2 viruses spanning nearly 65 years of antigenic drift, as well as a heterosubtypic N9 NA. Single B cell analyses identified a monoclonal antibody that competed with a component of the serum antibody response elicited by the hyperglycosylated immunogen, and structural characterization showed that it recognizes a previously undefined, conserved epitope at the NA tetramer interface. Passive transfer of this interface-directed antibody partially protected mice against lethal heterologous influenza challenge. Collectively, these data show that glycan shielding can reshape and enrich humoral responses toward a conserved antigenic region on NA. The immunogen and hyperglycosylation design strategy described here provide a template for developing next- generation NA-based influenza vaccines. ONE SENTENCE SUMMARYA hyperglycosylated influenza neuraminidase immunogen reshapes humoral immunity and elicits antibodies targeting a conserved tetramer-interface epitope.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Structural and Mechanistic Basis for Antibody Neutralization of the Measles Fusion Protein 95%
- Immunologic and Biophysical Features of the BNT162b2 JN.1- and KP.2-Adapted COVID-19 Vaccines 95%
- Characterization of two non-competing antibodies to influenza H3N2 hemagglutinin stem reveals its evolving antigenicity 95%
Similar papers in this journal
- Epistasis in the receptor binding domain of contemporary H3N2 viruses that reverted to bind sialylated diLacNAc repeats 95%
- Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design 95%
- Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice 94%
Similar papers in this journal
- Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial 96%
- Deep Mining of the Human Antibody Repertoire Identifies Frequent and Immunogenetically Diverse CDRH3 Topologies Targetable by Vaccination 95%
- Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.